FDA warning letters and recalls: the lookup guide

The three lookups that answer it yourself

Warning letters: FDA’s searchable warning-letter database — search the pharmacy or company name, read the letter itself (subject lines tell you if it’s sterility, misbranding, or unapproved-drug marketing). Recalls: FDA’s recall and safety-alert listings, searchable by drug name — match lot numbers against your vial. Adverse events: MedWatch, both to search signals and to report your own (1-800-FDA-1088) — reporting is the feedback loop.

FDA’s current GLP-1 concern areas, per its own statements

Unapproved salt forms (semaglutide sodium/acetate) marketed as semaglutide; dosing errors from unit-conversion confusion across compounded concentrations — the reason this site refuses to publish a units calculator; fraudulent and counterfeit product, especially “brand” pens at implausible prices; and mass-marketed “research” peptides (retatrutide included) sold outside any lawful human-use pathway. Each maps to a bright-line test on the legitimacy checklist.

The verified adverse-event figures — with the caveat welded on

As of May 31, 2026, FDA said it had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide — and FDA itself cautions that reports may be underreported and that a report does not by itself establish that the drug caused the event. Both figures were verified against FDA’s unapproved-GLP-1 concerns page on 2026-08-25. Quote them with the date and the causation caveat, or not at all.

What this desk records, and the standard for publishing it

When an enforcement action names a provider or pharmacy in our dataset, it gets recorded on that provider’s file with a link to the primary FDA document and a date — primary source or it doesn’t publish. This page updates as the dataset does; a blank ledger today means “nothing sourced yet,” never “nothing exists.”